Liver transplantation and hepatitis C: Will understanding the interleukin‐28B polymorphisms improve outcomes?
Geoffrey W. McCaughan, Nicholas A. Shackel, David G. Bowen – 14 January 2011
Differences in health‐related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors
Sammy Saab, Hillary Bownik, Noel Ayoub, Zobair Younossi, Francisco Durazo, Steven Han, Johnny C. Hong, Douglas Farmer, Ronald W. Busuttil – 14 January 2011 – One of the current ultimate goals of orthotopic liver transplantation (OLT) is the improvement of patients' health‐related quality of life (HRQOL). The purpose of this study was to look at the effects of socioeconomic and demographic differences on the short‐term and long‐term HRQOL outcomes of OLT recipients.
Malpositioned transjugular intrahepatic portosystemic shunt in the common hepatic duct leading to biliary obstruction and liver transplantation
Flavio Paterno, Adeel Khan, Keith Cavaness, Massimo Asolati, Jeffrey Campsen, Greg J. McKenna, Nicholas Onaca, Richard Ruiz, James Trotter, Goran B. Klintmalm – 14 January 2011
Development of a disease‐specific questionnaire to measure health‐related quality of life in liver transplant recipients
Sammy Saab, Vivian Ng, Carmen Landaverde, Sung‐Jae Lee, W. Scott Comulada, Jennifer Arevalo, Francisco Durazo, Steven‐Huy Han, Zobari Younossi, Ronald W. Busuttil – 14 January 2011 – Currently, no disease‐targeted instrument is available for measuring health‐related quality of life (HRQOL) in liver transplant recipients. We developed and tested a post–liver transplant quality of life (pLTQ) instrument. Item selection for the pLTQ instrument was based on responses from liver transplant recipients, 12 liver experts, and a literature search.
The price of “doing the right thing”
Richard B. Freeman – 14 January 2011
Operational tolerance: Past lessons and future prospects
Josh Levitsky – 14 January 2011 – Every liver transplant (LT) center has had patients who either self‐discontinue immunosuppressive (IS) therapy or are deliberately withdrawn due to a research protocol or clinical concern (ie, lymphoproliferative disorder [LPD], overwhelming infection). This is understandable because maintenance IS therapy, particularly calcineurin inhibitors (CNI), is associated with significant cost, side effects, and considerable long‐term morbidity and mortality.
A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation
Robert M. Weinrieb, Deborah H.A. Van Horn, Kevin G. Lynch, Michael R. Lucey – 14 January 2011 – Alcohol is the second most common cause of cirrhosis necessitating liver transplantation in the United States, yet rates of posttransplant drinking approach 50% and no controlled clinical trials of alcoholism treatment exist in this population. Eligible patients were randomly assigned to receive Motivational Enhancement Therapy (MET), or referral to local treatment sources (“treatment as usual” [TAU]). Addictive behavior, mood states, and general health were compared.
Does cardiac dysfunction explain deleterious effects of beta‐blockers in cirrhosis and refractory ascites?
Aleksander Krag, Flemming Bendtsen, Søren Møller – 12 January 2011
The deleterious effects of propranolol on patients with cirrhosis
Cumali Efe, Tugrul Purnak, Ersan Ozaslan – 12 January 2011
Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification
Maxime Ronot, Stephane Bahrami, Julien Calderaro, Dominique‐Charles Valla, Pierre Bedossa, Jacques Belghti, Valérie Vilgrain, Valérie Paradis – 12 January 2011 – Hepatocellular adenomas (HCAs) are divided into genotype/phenotype subgroups associated with different evolutive profiles. Therefore, recognition of subtype is of clinical importance in patient management. Magnetic resonance imaging (MRI) is considered the most informative imaging modality and liver biopsy a key diagnostic tool whose role in HCA subtyping has never been extensively studied.